Articolo
5 minuti di lettura
19 febbraio 2026
SALUTE RESPIRATORIA
prod:prod_dcx-login
L’esigenza
Globally, co-circulation of SARS-CoV-2, influenza and respiratory syncytial virus (RSV) was observed during the 2022 respiratory season with the easing of COVID-19 measures. This led to increased burden on healthcare infrastructure and increased risk of severe illness for high-risk populations.1.2
- Rapid testing to facilitate early diagnosis of high-risk patient populations and adoption of respiratory multiplexed tests with the integration of SARS-CoV-2 testing are required.5
- Ensure the accuracy of test performance despite new SARS-CoV-2 variants4 and influenza A mutations.3
- Rapid testing results to facilitate early diagnosis for effective patient management.5
- Multiplexing ability for the most prevalent and actionable pathogens (SARS-CoV-2, influenza A, influenza B, RSV) to simplify the diagnosis process.
1 Tam JS, Shu Y. Public Health Control Measures for the Co-circulation of Influenza and SARS-CoV-2 During Influenza Seasons. China CDC Wkly. 2022 Jan 14;4(2):22-26. doi: 10.46234/ccdcw2021.228. PMID: 35586519; PMCID: PMC8796727.
2 https://www.ecdc.europa.eu/en/publications-data/intensified-circulation-respiratory-syncytial-virus-rsv-and-associated-hospital
3 Jørgensen, R. L. et al. Emergence of circulating influenza A H3N2 viruses with genetic drift in the matrix gene: be alert of false-negative test results. APMIS 130, 612–617 (2022).
4 https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests|
5 Strategic preparedness and response plan: April ‘23 –’25
2 https://www.ecdc.europa.eu/en/publications-data/intensified-circulation-respiratory-syncytial-virus-rsv-and-associated-hospital
3 Jørgensen, R. L. et al. Emergence of circulating influenza A H3N2 viruses with genetic drift in the matrix gene: be alert of false-negative test results. APMIS 130, 612–617 (2022).
4 https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests|
5 Strategic preparedness and response plan: April ‘23 –’25
La soluzione
The Xpert Xpress CoV-2/Flu/RSV plus test is a multiplexed real-time PCR test intended for the simultaneous in vitro qualitative detection and differentiation of RNA from SARS-CoV-2, influenza A, influenza B, and/or RSV in nasopharyngeal swab or anterior nasal swab specimens collected from individuals with signs and/or symptoms of respiratory viral infection.
The Xpert Xpress CoV-2/Flu/RSV plus test:
The Xpert Xpress CoV-2/Flu/RSV plus test:
- Provides fast and accurate results in as early as 25 minutes# for SARS-CoV-2.
- Utilizes a multi-gene target approach for the detection of SARS-CoV-2 and influenza providing target redundancy to mitigate the potential impact of genetic shift and drift on strain detection.
- Detects SARS-CoV-2, influenza A, influenza B, and/or RSV simultaneously.
# With Early Assay Termination (EAT) for positive results.
L’impatto
- Xpert Xpress CoV-2/Flu/RSV plus allows for accurate and rapid results, optimizing diagnostic efficiency and supporting informed clinical assessment.6
- Testing with Xpert Xpress CoV-2/Flu/RSV plus may result in significant cost-savings compared to antigen and send-out PCR testing strategies and may be associated with fewer hospitalizations, ICU admissions, mechanical ventilations, and deaths as described in published health-economic analyses.6
- Results that may reduce the need for reflex and/or confirmatory testing.7
6 Davies, E. Boller, A. Beaubrun, C. Miller, I. Jensen. (2023) A Cost-Consequence Analysis of Xpert Xpress CoV-2/Flu/RSV Plus for the Diagnosis of Viral Respiratory Infections from a US Health Plan Perspective.J Mol Diagn, 25(11) (S1-S186): S64. https://www.jmdjournal.org/article/S1525-1578%2823%2900249-0/pdf
7 K. Stockl, J. Tucker, J. Certa, A. Beaubrun, K. Schwebke. (2023). Use of Antigen and Molecular Testing for Coronavirus 2019 (SARS-CoV-2) among Patients with Influenza-Like Illness (ILI) in the Non-inpatient Setting. J Mol Diagn, 25(11) (S1-S186): S53. https://www.jmdjournal.org/article/S1525-1578%2823%2900249-0/pdf
questo test non è stato autorizzato né approvato dalla FDA. Questo test è stato autorizzato dalla FDA per l’uso da parte di laboratori autorizzati ai sensi di un’autorizzazione all’uso in emergenza (EUA). Xpert Xpress CoV-2/Flu/RSV plus plus è stato autorizzato solo per il simultaneo rilevamento qualitativo e la differenziazione di acidi nucleici del SARS-CoV-2, dell’influenza A, dell’influenza B e del virus respiratorio sinciziale (RSV), e non per altri virus o patogeni. L’uso in emergenza di questo prodotto è autorizzato soltanto per la durata della dichiarazione secondo cui esistono circostanze tali da giustificare l’autorizzazione all’uso in emergenza di test diagnostici in vitro per il rilevamento e/o la diagnosi di COVID-19 ai sensi della Sezione 564(b)(1) del Federal Food, Drug and Cosmetic Act, 21 U.S.C.
360bbb-3(b)(1), salvo laddove l’autorizzazione sia sospesa o revocata anticipatamente.
7 K. Stockl, J. Tucker, J. Certa, A. Beaubrun, K. Schwebke. (2023). Use of Antigen and Molecular Testing for Coronavirus 2019 (SARS-CoV-2) among Patients with Influenza-Like Illness (ILI) in the Non-inpatient Setting. J Mol Diagn, 25(11) (S1-S186): S53. https://www.jmdjournal.org/article/S1525-1578%2823%2900249-0/pdf
questo test non è stato autorizzato né approvato dalla FDA. Questo test è stato autorizzato dalla FDA per l’uso da parte di laboratori autorizzati ai sensi di un’autorizzazione all’uso in emergenza (EUA). Xpert Xpress CoV-2/Flu/RSV plus plus è stato autorizzato solo per il simultaneo rilevamento qualitativo e la differenziazione di acidi nucleici del SARS-CoV-2, dell’influenza A, dell’influenza B e del virus respiratorio sinciziale (RSV), e non per altri virus o patogeni. L’uso in emergenza di questo prodotto è autorizzato soltanto per la durata della dichiarazione secondo cui esistono circostanze tali da giustificare l’autorizzazione all’uso in emergenza di test diagnostici in vitro per il rilevamento e/o la diagnosi di COVID-19 ai sensi della Sezione 564(b)(1) del Federal Food, Drug and Cosmetic Act, 21 U.S.C.
360bbb-3(b)(1), salvo laddove l’autorizzazione sia sospesa o revocata anticipatamente.
